1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.
Funding Opportunity Number: HT942526MSRPCTA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $4M total program funding.
Get alerted about grants like this
Get emailed when new opportunities from “Defense Health Agency Contracting Activity - DHACA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $4M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Multiple Sclerosis Clinical Trial Award are due August 13, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Multiple Sclerosis Clinical Trial Award is offered by Defense Health Agency Contracting Activity - DHACA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
RWJF's Health Equity Research for Action puts up ~20 grants of up to $500,000 — but demands a two-year community partnership and a community co-PI. Here's the strategy, set against the brightest foundation-giving outlook since 2022.
Read articleCMS awarded all 50 states a slice of the $50 billion Rural Health Transformation Program on December 29, 2025 — first-year checks average $200M, ranging from $147M to $281M. The federal application is closed and you cannot apply to CMS. The money reaches hospitals, clinics, and nonprofits only as state subawards, and those competitions open through 2026. Here is how the formula worked, what the funds can and cannot buy, and how to position for a subaward before the money starts flowing.
Read articleThe Defense Production Act's Title III has quietly become one of the most active federal funding vehicles of 2026 — $500M for energy infrastructure, ~$275M for critical-minerals processing, and a standing defense-manufacturing FOA. But the underlying authorities sunset September 30, 2026 absent reauthorization. Here is how DPA Title III works, who is eligible, why it differs from a normal grant, and how to move before the window closes.
Read article